{
    "clinical_study": {
        "@rank": "122951", 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die.\n\n      PURPOSE: Phase II trial to study the effectiveness of fenretinide in treating patients who\n      have advanced kidney cancer."
        }, 
        "brief_title": "Chemotherapy in Treating Patients With Advanced Kidney Cancer", 
        "completion_date": {
            "#text": "October 2005", 
            "@type": "Actual"
        }, 
        "condition": "Kidney Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Renal Cell", 
                "Kidney Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the response rate of patients with advanced renal cell carcinoma treated with\n           fenretinide.\n\n        -  Determine progression-free and overall survival of this patient population treated with\n           this drug.\n\n        -  Determine the quantitative and qualitative toxic effects of this drug in these\n           patients.\n\n      OUTLINE: Patients receive oral fenretinide twice a day for 7 days. Courses repeat every 21\n      days in the absence of unacceptable toxicity or disease progression.\n\n      PROJECTED ACCRUAL: Approximately 18-35 patients will be accrued for this study within 9-21\n      months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically or cytologically confirmed locally advanced unresectable, locally\n             recurrent, or metastatic renal cell carcinoma\n\n          -  Measurable disease\n\n               -  At least 20 mm with conventional techniques OR\n\n               -  At least 10 mm with spiral CT scan\n\n          -  No nonmeasurable disease only including:\n\n               -  Bone lesions\n\n               -  Leptomeningeal disease\n\n               -  Ascites\n\n               -  Pleural/pericardial effusion\n\n               -  Lymphangitis cutis/pulmonis\n\n               -  Abdominal masses not confirmed and followed by imaging techniques\n\n               -  Cystic lesions\n\n          -  No known brain metastases\n\n               -  History of brain metastases that have been resected and/or irradiated with\n                  subsequent normal brain CT scan allowed\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  18 and over\n\n        Performance status:\n\n          -  ECOG 0-2 OR\n\n          -  Karnofsky 60-100%\n\n        Life expectancy:\n\n          -  More than 12 weeks\n\n        Hematopoietic:\n\n          -  Absolute neutrophil count at least 1,500/mm3\n\n          -  Platelet count at least 100,000/mm3\n\n        Hepatic:\n\n          -  Bilirubin no greater than 1.5 mg/dL\n\n          -  AST no greater than 2.5 times upper limit of normal\n\n        Renal:\n\n          -  Creatinine no greater than 2 mg/dL OR\n\n          -  Creatinine clearance at least 60 mL/min\n\n        Cardiovascular:\n\n          -  No symptomatic congestive heart failure, unstable angina pectoris, or cardiac\n             arrhythmia\n\n        Other:\n\n          -  Not pregnant or nursing\n\n          -  Fertile patients must use effective contraception\n\n          -  No other prior malignancy within the past 2 years except nonmelanoma skin cancer or\n             carcinoma in situ of any site\n\n          -  No history of allergic reactions attributed to compounds of similar chemical or\n             biologic composition to fenretinide\n\n          -  No other concurrent uncontrolled illness (e.g., ongoing or active infection)\n\n          -  No concurrent psychiatric illness or social situation that would preclude study\n\n          -  History of HIV allowed if no active infection or history of retinitis\n\n          -  No history of retinal disease, night blindness, or difficulty seeing in the dark\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  Prior biologic therapy allowed\n\n        Chemotherapy:\n\n          -  No more than 1 prior chemotherapy regimen\n\n        Endocrine therapy:\n\n          -  Not specified\n\n        Radiotherapy:\n\n          -  See Disease Characteristics\n\n          -  At least 4 weeks since prior radiotherapy\n\n        Surgery:\n\n          -  See Disease Characteristics\n\n        Other:\n\n          -  Recovered from prior therapy\n\n          -  No prior systemic retinoid therapy\n\n          -  No concurrent antioxidants (e.g., ascorbic acid or vitamin E)\n\n          -  No other concurrent therapy for renal cell carcinoma"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "March 3, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00011973", 
            "org_study_id": "CDR0000068465", 
            "secondary_id": [
                "U01CA062487", 
                "P30CA022453", 
                "WSU-C-2232", 
                "NCI-WSU-910"
            ]
        }, 
        "intervention": {
            "intervention_name": "fenretinide", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Fenretinide"
        }, 
        "keyword": [
            "stage III renal cell cancer", 
            "stage IV renal cell cancer", 
            "recurrent renal cell cancer"
        ], 
        "lastchanged_date": "April 3, 2013", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/WSU-C-2232"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48201-1379"
                    }, 
                    "name": "Barbara Ann Karmanos Cancer Institute"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55905"
                    }, 
                    "name": "Mayo Clinic Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19104-4283"
                    }, 
                    "name": "University of Pennsylvania Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030-4009"
                    }, 
                    "name": "University of Texas - MD Anderson Cancer Center"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase Two Study Of Fenretinide In Renal Cell Cancer", 
        "overall_official": {
            "affiliation": "Barbara Ann Karmanos Cancer Institute", 
            "last_name": "Ulka N. Vaishampayan, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2005", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00011973"
        }, 
        "results_reference": {
            "PMID": "15744595", 
            "citation": "Vaishampayan U, Heilbrun LK, Parchment RE, Jain V, Zwiebel J, Boinpally RR, LoRusso P, Hussain M. Phase II trial of fenretinide in advanced renal carcinoma. Invest New Drugs. 2005 Mar;23(2):179-85."
        }, 
        "source": "Barbara Ann Karmanos Cancer Institute", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Barbara Ann Karmanos Cancer Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2000", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }, 
    "geocoordinates": {
        "Barbara Ann Karmanos Cancer Institute": "42.331 -83.046", 
        "Mayo Clinic Cancer Center": "44.022 -92.47", 
        "University of Pennsylvania Cancer Center": "39.952 -75.164", 
        "University of Texas - MD Anderson Cancer Center": "29.76 -95.369"
    }
}